Verastem Oncology to Present at Upcoming Investor Conferences
September 10 2020 - 4:05PM
Business Wire
Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology),
a biopharmaceutical company committed to developing and
commercializing new medicines for patients battling cancer, today
announced that management will present virtually at the following
upcoming investor conferences:
- H.C. Wainwright 22nd Annual Global Investment Conference on
Monday, September 14, 2020 at 1:30 p.m. Eastern Time
- Cantor Virtual Global Healthcare Conference on Thursday,
September 17, 2020 at 3:20 p.m. Eastern Time
A live webcast of the presentations will be available on the
investors section of the Company’s website at www.verastem.com. An
archived presentation will be available for 90 days.
About Verastem Oncology
Verastem Oncology (Nasdaq: VSTM) is a development-stage
biopharmaceutical company committed to the development and
commercialization of new medicines to improve the lives of patients
diagnosed with cancer. Our pipeline is focused on novel small
molecule drugs that inhibit critical signaling pathways in cancer
that promote cancer cell survival and tumor growth, including
RAF/MEK inhibition and focal adhesion kinase (FAK) inhibition. For
more information, please visit www.verastem.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200910005802/en/
Verastem Oncology Contacts: Investors: John Doyle Vice
President, Investor Relations & Finance +1 781-469-1546
jdoyle@verastem.com Media: Lisa Buffington Corporate Communications
+1 781-292-4205 lbuffington@verastem.com
Verastem (NASDAQ:VSTM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Verastem (NASDAQ:VSTM)
Historical Stock Chart
From Sep 2023 to Sep 2024